ProfileGDS5678 / 1449221_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 83% 81% 82% 78% 80% 80% 80% 81% 82% 79% 80% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6667180
GSM967853U87-EV human glioblastoma xenograft - Control 25.7287280
GSM967854U87-EV human glioblastoma xenograft - Control 36.01483
GSM967855U87-EV human glioblastoma xenograft - Control 45.9890481
GSM967856U87-EV human glioblastoma xenograft - Control 55.9853482
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2710678
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5564980
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6634580
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6042680
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8034981
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9193282
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5160379
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6666780
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4480679